Semaglutide may protect kidney function in individuals with overweight or obesity and cardiovascular disease
The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular ...
May 25, 2024
0
1